Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


07.09.2020

3 AJR Am J Roentgenol
3 Anticancer Res
1 BJU Int
1 BMC Cancer
3 BMC Urol
1 Eur J Radiol
1 Eur Radiol
3 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 J Clin Oncol
1 Magn Reson Imaging
1 Mod Pathol
1 PLoS One
1 Proc Natl Acad Sci U S A
1 Prostate
3 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. COSTA DN, Jia L, Subramanian N, Xi Y, et al
    Prospectively-Reported PI-RADS Version 2.1 Atypical Benign Prostatic Hyperplasia Nodules with Marked Restricted Diffusion ('2+1' Transition Zone Lesions): Clinically Significant Prostate Cancer Detection Rates on Multiparametric MRI.
    AJR Am J Roentgenol. 2020 Sep 2. doi: 10.2214/AJR.20.24370.
    PubMed         Abstract available

  2. GUPTA RT
    Editorial Comment on "Prevalence of prostate cancer in PI-RADS version 2.1 transition zone 'atypical nodules' upgraded by abnormal diffusion weighted imaging: correlation with MRI-directed TRUS-guided targeted biopsy".
    AJR Am J Roentgenol. 2020 Sep 2. doi: 10.2214/AJR.20.24501.
    PubMed        

  3. WALKER SM, Mehralivand S, Harmon SA, Sanford T, et al
    Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection.
    AJR Am J Roentgenol. 2020 Sep 2:1-6. doi: 10.2214/AJR.19.22679.
    PubMed         Abstract available


    Anticancer Res

  4. MIYAO T, Koike H, Sekine Y, Ohtsu A, et al
    YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression.
    Anticancer Res. 2020;40:5091-5095.
    PubMed         Abstract available

  5. ISHII A, Shigemura K, Kitagawa K, Sung SY, et al
    Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5107-5114.
    PubMed         Abstract available

  6. MINAMI H, Ando Y, Tamura K, Tajima T, et al
    Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:5229-5235.
    PubMed         Abstract available


    BJU Int

  7. ODERDA M, Diamand R, Albisinni S, Calleris G, et al
    Indications and complications of pelvic lymph node dissection for prostate cancer: are currently available nomograms accurate to predict lymph node invasion?
    BJU Int. 2020 Sep 1. doi: 10.1111/bju.15220.
    PubMed         Abstract available


    BMC Cancer

  8. CARIO CL, Chen E, Leong L, Emami NC, et al
    A machine learning approach to optimizing cell-free DNA sequencing panels: with an application to prostate cancer.
    BMC Cancer. 2020;20:820.
    PubMed         Abstract available


    BMC Urol

  9. FANG CW, Chen CH, Muo CH, Wu SC, et al
    Risk of subsequent prostate cancer in peptic ulcer patients who received helicobacter pylori eradication therapy: an Asian population-based cohort study.
    BMC Urol. 2020;20:135.
    PubMed         Abstract available

  10. MCKIERNAN J, Noerholm M, Tadigotla V, Kumar S, et al
    A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
    BMC Urol. 2020;20:138.
    PubMed         Abstract available

  11. UEMURA H, Koroki Y, Iwaki Y, Imanaka K, et al
    Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
    BMC Urol. 2020;20:139.
    PubMed         Abstract available


    Eur J Radiol

  12. BARRAL M, Jemal-Turki A, Beuvon F, Soyer P, et al
    Cellular density of low-grade transition zone prostate cancer: A limiting factor to correlate restricted diffusion with tumor aggressiveness.
    Eur J Radiol. 2020;131:109230.
    PubMed         Abstract available


    Eur Radiol

  13. SHIRADKAR R, Panda A, Leo P, Janowczyk A, et al
    T1 and T2 MR fingerprinting measurements of prostate cancer and prostatitis correlate with deep learning-derived estimates of epithelium, lumen, and stromal composition on corresponding whole mount histopathology.
    Eur Radiol. 2020 Sep 2. pii: 10.1007/s00330-020-07214.
    PubMed         Abstract available


    Eur Urol

  14. PADHANI AR, Barentsz J, Weinreb J, Schoots I, et al
    Re: Variability of the Positive Predictive Value of PI-RADS for Prostate MRI Across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel.
    Eur Urol. 2020 Aug 25. pii: S0302-2838(20)30444.
    PubMed        

  15. MAHAL BA, D'Amico AV, Nguyen PL
    Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Eur Urol. 2020 Aug 28. pii: S0302-2838(20)30602.
    PubMed        

  16. DE SANTIS M, Mottet N, Cornford P, Gillessen S, et al
    Precision Oncology for Metastatic Prostate Cancer: Translation into Practice.
    Eur Urol. 2020 Aug 27. pii: S0302-2838(20)30638.
    PubMed         Abstract available


    Int J Cancer

  17. WOKOLORCZYK D, Kluzniak W, Huzarski T, Gronwald J, et al
    Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Int J Cancer. 2020 Sep 1. doi: 10.1002/ijc.33272.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  18. HALL WA, Paulson E, Davis BJ, Spratt DE, et al
    NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Post-Operative Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020 Aug 27. pii: S0360-3016(20)34124.
    PubMed         Abstract available


    Int J Urol

  19. SHOJI S
    Editorial Comment from Dr Shoji to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14353.
    PubMed        

  20. KANEKO M, Yip W, Abreu AL
    Editorial Comment from Dr Kaneko et al. to Focal bipolar radiofrequency ablation for localized prostate cancer: Safety and feasibility.
    Int J Urol. 2020 Aug 29. doi: 10.1111/iju.14362.
    PubMed        


    J Clin Oncol

  21. MARKOWSKI MC, Antonarakis ES
    BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
    J Clin Oncol. 2020 Sep 1:JCO2002246. doi: 10.1200/JCO.20.02246.
    PubMed        


    Magn Reson Imaging

  22. PARK S, Park JG, Jun S, Kim H, et al
    Differentiation of bone metastases from prostate cancer and benign red marrow depositions of the pelvic bone with multiparametric MRI.
    Magn Reson Imaging. 2020 Aug 26. pii: S0730-725X(19)30749.
    PubMed         Abstract available


    Mod Pathol

  23. HARMON SA, Patel PG, Sanford TH, Caven I, et al
    High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts.
    Mod Pathol. 2020 Sep 3. pii: 10.1038/s41379-020-00674.
    PubMed         Abstract available


    PLoS One

  24. STROOMBERG HV, Jorgensen A, Brasso K, Nielsen JE, et al
    Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients.
    PLoS One. 2020;15:e0238814.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  25. ALUMKAL JJ, Sun D, Lu E, Beer TM, et al
    Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
    Proc Natl Acad Sci U S A. 2020;117:12315-12323.
    PubMed         Abstract available


    Prostate

  26. MIYAHIRA AK, Pienta KJ, Babich JW, Bander NH, et al
    Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
    Prostate. 2020 Aug 31. doi: 10.1002/pros.24056.
    PubMed         Abstract available


    Urology

  27. WAKE N, Bjurlin MA
    Author Reply: 3D Printing, Augmented Reality, and Virtual Reality for the Assessment and Management of Kidney and Prostate Cancer: A Systematic Review.
    Urology. 2020 Aug 28. pii: S0090-4295(20)31010.
    PubMed        

  28. THOMAS L, Sharifi N
    Germline HSD3B1 Genetics and Prostate Cancer Outcomes.
    Urology. 2020 Aug 28. pii: S0090-4295(20)31025.
    PubMed         Abstract available

  29. KARSIYAKALI N, Ozgen MB, Ozveren B, Akbal C, et al
    Sub-optimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy.
    Urology. 2020 Aug 29. pii: S0090-4295(20)31028.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: